Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1986 Jul;6(4):299-305.
doi: 10.1007/BF00917330.

Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome

Case Reports

Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome

F Merino et al. J Clin Immunol. 1986 Jul.

Abstract

The results of clinical and Epstein-Barr virus (EBV) serological studies on nine Chediak-Higashi syndrome (CHS) patients are reported. Persistently elevated antibodies to the viral capsid antigen (VCA) and the restricted component of the early antigen complex (EA-R) developed in six patients who experienced primary EBV infection which either remained silent or were accompanied by clinical signs of infectious mononucleosis (IM). Hepatosplenomegaly and moderate lymphadenopathy, both clinical signs of the accelerated phase, remained detectable in the six patients for a long period of time after seroconversion. The clinical, serological, and histopathological observations are suggestive of a nonmalignant lymphoproliferative disease and consistent with an immunodeficiency to EBV. The abnormal serological responses to EBV in CHS are therefore considered manifestations of a chronic active EBV infection which may result in lethal lymphoproliferation. The three as yet seronegative CHS patients revealed no signs of the accelerated lymphoproliferative phase of the syndrome.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Int J Cancer. 1985 Jan 15;35(1):35-42 - PubMed
    1. Immunol Lett. 1986 Jan;12(1):51-4 - PubMed
    1. J Immunol. 1983 Jun;130(6):2671-4 - PubMed
    1. Lab Invest. 1966 Oct;15(10):1634-42 - PubMed
    1. Clin Immunol Immunopathol. 1984 Mar;30(3):437-50 - PubMed

Publication types